ArticleObesity surgery2026
Weight Loss Threshold and Inflection Points for Biochemical Remission of Male Obesity-Associated Secondary Hypogonadism After Sleeve Gastrectomy.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMale obesity-associated secondary hypogonadism (MOSH) is common in men with obesity and can improve following metabolic bariatric surgery (MBS). However, the quantitative relationship between postoperative weight loss and biochemical remission of MOSH remains unclear. This study aimed to characterize the nonlinear association between percentage total weight loss (TWL%) and MOSH remission after laparoscopic sleeve gastrectomy (LSG), and to identify clinically relevant weight-loss thresholds.
methodsThis retrospective study included MOSH patients undergoing LSG with one-year follow-up. Restricted cubic spline (RCS) modeling evaluated the nonlinear relationship between TWL% and remission. Patients were grouped by RCS-derived thresholds, and logistic regression with interaction analyses examined the association and effect modification.
resultsAmong 230 patients, mean TWL% was 31.60% and remission rate was 82.17% at one year after LSG. RCS revealed a nonlinear association (P = 0.041) with an exploratory effect-initiation threshold at 21.8% TWL% and a suggested plateau period at 36.0% TWL%. Corresponding remission rates were 47.1% (< 21.8% TWL%), 88.9% (21.8-36.0% TWL%), and 87.1% (≥ 36.0% TWL%). Both higher TWL% groups had significantly greater odds of remission compared with the lowest group (adjusted odds ratio [aOR]: 10.61 and 10.64, respectively). Age, preoperative body mass index (BMI), and type 2 diabetes mellitus (T2DM) did not modify the relationship.
conclusionAchieving 21.8% TWL% may represent an exploratory lower threshold for high remission probability, while 36.0% TWL% may indicate the onset of a plateau period. These findings provide preliminary reference points that require prospective validation before being considered for clinical guidance. KEY POINTS: • 21.8% TWL% may represent an exploratory minimum threshold for high MOSH remission probability after LSG. • 36.0% TWL% may indicate a plateau; further weight loss appears to yield no additional remission benefit. • These exploratory thresholds showed consistency across age, preoperative BMI, and T2DM subgroups in this cohort.
Indexed as
Identifiers
42671498What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.